NCT03340506 2026-04-01Dabrafenib and/or Trametinib Rollover StudyNovartisPhase 4 Recruiting100 enrolled
NCT07486713 2026-03-20Olutasidenib DDI Study in Patients With IDH1 Mutation Positive MalignanciesRigel PharmaceuticalsPhase 4 Recruiting16 enrolled